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Introduction
Th   e term interstitial lung disease (ILD) is used to describe 
a heterogeneous group of parenchymal lung disorders 
that share common radiologic, pathologic, and clinical 
mani  festations. ILD in its various guises can be asymp-
tomatic but detected by high-resolution computed tomo-
graphy (HRCT) of the chest or by pulmonary function 
tests. Th  e  ﬁ  brosing forms of ILD are often incurable, and 
are associated with signiﬁ  cant morbidity and mortality.
ILD is subdivided into idiopathic interstitial pneu-
monia, of which idiopathic pulmonary ﬁ  brosis (IPF) is 
one subset, and diﬀ  use parenchymal lung diseases, which 
may be secondary to a variety of occupational or 
environmental exposures, or – as discussed in the present 
review – can complicate multiple rheumatic or connec-
tive tissue diseases (CTDs). Th  ese diseases include sys-
temic sclerosis (SSc), where ILD occurs in a majority of 
patients, and rheumatoid arthritis (RA), polymyositis/
dermato  myositis (PM/DM), Sjögren’s syndrome, sys  temic 
lupus erythematosus (SLE), undiﬀ  erentiated CTD, and 
mixed CTD, where ILD is a less frequent complication 
(Table 1). In addition to ILD, other forms of lung damage 
involving the pleura, vasculature, airways, and lymphatic 
tissues can complicate CTDs. Th  ese complications will 
not be covered in the present review.
Th   e frequency of ILD in CTDs varies based on patient 
selection and the methods used for detection. In general, 
the prevalence appears to be higher than previously 
thought. Th  e clinical presentation is variable, ranging 
from cough to pleuritic pain and progressive shortness of 
breath. In some patients, ILD may be the presenting 
feature that predates the rheumatic disease, while in 
others the rheumatic symptoms predate ILD. Early 
recog  nition of pulmonary involvement in these patients 
is important for initiating appropriate therapy.
Multidisciplinary combined connective tissue disease-
associated interstitial lung disease (CTD-ILD) clinics with 
rheumatologists and respiratory specialists are being 
established at many academic medical centers. Recent 
experience from one CTD-ILD clinic (at Brigham and 
Women’s Hospital, Boston, MA, USA) indicates that, 
after combined evaluation by both a pulmonologist and a 
rheumatologist, 50% of patients referred with an initial 
concern for IPF or another CTD-ILD had their diagnosis 
changed to a CTD-ILD [1].
Th   e underlying pathology in CTD-ILD is dominated by 
inﬂ  ammation or ﬁ  brosis, or a combination of both with 
distinct radiologic and histopathologic patterns. Th  ese 
patterns are nonspeciﬁ  c interstitial pneumonia (NSIP), 
usual interstitial pneumonia (UIP), desquamative inter-
stitial pneumonia, cryptogenic organizing pneu  monia, 
diﬀ   use alveolar damage, acute interstitial pneu  monia, 
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© 2010 BioMed Central Ltdand lymphocytic interstitial pneumonia. Table 2 outlines 
the characteristic histopathologic and radiologic features 
of the diﬀ  erent forms of ILD. Th  e present review will 
primarily focus on the pathogenesis and treatment of 
SSc-associated ILD, with a brief overview of the other 
CTD-ILDs.
Systemic sclerosis
SSc is characterized by tissue injury leading to excessive 
collagen deposition, and pulmonary disease is a leading 
cause of death in these patients.
Most patients with SSc have evidence of ILD by HRCT 
of the chest or at autopsy. Close to one-half of cases 
develop clinically signiﬁ  cant ILD. In a multiethnic study, 
the risk for ILD in cases of SSc was greater in patients of 
African-American ethnicity and in those patients with 
more extensive skin and cardiac involvement [2]. Auto-
antibody expression is a predictor of internal organ 
involvement, particularly lung involvement. Th  e  presence 
of anti-topoisomerase antibodies (Scl-70) is strongly 
associated with development of signiﬁ   cant ILD, while 
anti-centromere antibodies appear to be protective 
– although patients with limited SSc are not excluded 
from developing ILD [2,3]. A recent European League 
Against Rheumatism Scleroderma Trials and Research 
analysis revealed in a cohort of 3,656 SSc patients that 
ILD was present in 53% of cases with diﬀ  use cutaneous 
SSc and in 35% of cases with limited cutaneous SSc [4].
Biomarkers, although currently not available for clinical 
testing, may serve as indicators of disease and as predic-
tors of progression. Serum levels of surfactant proteins A 
and D (SP-A and SP-D) and the glycoprotein Krebs von 
den lungen-6 (KL-6), produced by type II alveolar epi-
thelial cells, are elevated in sera of patients with ILD [5]. 
A comparison of SP-D and KL-6 serum concentrations 
showed that both markers were elevated in patients with 
SSc-associated ILD compared with healthy controls, with 
SP-D being more sensitive and KL-6 more speciﬁ  c [5]. 
Th  ere is a great deal of current interest in novel 
biomarkers such as chitinase-like protein YKL-40, which 
is already shown to be useful in asthma [6].
Histologically, SSc-associated ILD is characterized by 
early pulmonary inﬁ   ltration of inﬂ   ammatory cells and 
subsequent ﬁ  brosis of the lung parenchyma. Th  e most 
Table 1. Interstitial lung diseases associated with connective tissue diseases
Rheumatic disease  Frequency of ILD (%)  Comment
Systemic sclerosis  45 (clinically signifi  cant)  More common in diff  use disease; topoisomerase-1 antibodies
Rheumatoid arthritis  20 to 30  Increased risk with cigarette smoking 
Polymyositis/dermatomyositis  20 to 50a  More common with anti-synthetase antibodies
Sjögren’s syndrome  Up to 25  –
Systemic lupus erythematosus  2 to 8  Usually in patients with multisystem disease
Mixed connective tissue disease  20 to 60  –
ILD, interstitial lung disease. aFrequency may be higher based on recent studies.
Table 2. Characteristic histopathologic patterns and radiologic fi  ndings in the interstitium of IPF and connective tissue-
associated ILD
Disease association  Characteristic histopathologic pattern  Characteristic radiographic fi  ndings on HRCT
Idiopathic pulmonary fi  brosis  Usual interstitial pneumonia  Peripheral and bibasilar reticulonodular opacities with honeycombing
Systemic sclerosis  Nonspecifi  c interstitial pneumonia   Increased reticular markings, ground glass opacifi  cation, basilar prominence
  Usual interstitial pneumonia  Peripheral and bibasilar reticulonodular opacities with honeycombing
Rheumatoid arthritis  Usual interstitial pneumonia  Reticular changes and honeycombing
  Nonspecifi  c interstitial pneumonia  Ground-glass opacities with basilar prominence
Polymyositis/dermatomyositis  Nonspecifi  c interstitial pneumonia  As above
  Usual interstitial pneumonia   As above
  Cryptogenic organizing pneumonia  Patchy airspace consolidation, ground glass opacities
 Diff  use alveolar damage  Diff  use ground glass opacities 
Sjögren’s syndrome  Nonspecifi  c interstitial pneumonia  As above
  Lymphocytic interstitial pneumonia  Thin walled cysts, ground glass opacities, centrilobular nodules
Systemic lupus erythematosus  Acute interstitial pneumonia  Ground glass opacities
Mixed connective tissue disease  Nonspecifi  c interstitial pneumonia  Septal thickening and ground glass opacities
HRCT, high-resolution computed tomography; ILD, interstitial lung disease; IPF, idiopathic pulmonary fi  brosis.
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NSIP; the UIP pattern is less common. Histologically, 
NSIP is characterized by varying degrees of inﬂ  ammation 
and ﬁ   brosis, with the majority of patients showing 
prominent inﬂ  ammation. In contrast, UIP is charac  ter-
ized by dense patchy ﬁ   brosis with honeycombing, 
primarily in a subpleural distribution.
Radiologic ﬁ  ndings associated with CTDs are summar-
ized in Table 2. SSc-associated ILD is characterized on 
chest X-ray by hazy, reticular inﬁ  ltrates that are promi-
nent in the lower lobes. HRCT characteristically reveals 
ground glass opacities, traction bronchiectasis, and 
minimal honeycombing consistent with an NSIP pattern 
(Figure 1a). In contrast, the UIP pattern of IPF is 
characterized by patchy reticular opacities associated 
with traction bronchiectasis and honeycombing with a 
predominantly basal and peripheral reticular pattern 
(Figure 1b). Th  e utility of HRCT to detect histologic 
pattern is suﬃ   cient to make the diagnosis of UIP/IPF in 
50 to 60% of cases [7].
Pathogenesis of connective tissue disease-
associated interstitial lung diseases
Mediators of lung fi  brosis in systemic sclerosis
Interstitial lung involvement in SSc develops from an 
inter  play of autoimmunity, inﬂ  ammation, and vascular 
injury. Endothelial or epithelial injury is thought to pre-
cede inﬂ  ammation and ﬁ  brosis, but the mechanisms that 
perpetuate pulmonary ﬁ  brosis are still not fully under-
stood (Figure 2).
A number of proinﬂ  ammatory and proﬁ  brotic extra-
cellular mediators have been implicated in the patho-
genesis of interstitial lung diseases and IPF, and are also 
likely to have important roles in SSc-associated ILD. 
Th  ese include chemokines, cytokines, growth factors, 
lipids, and prostanoids. Th   e pivotal mediator of ﬁ  brosis is 
the multifunctional cytokine, transforming growth factor 
beta (TGFβ). Substantial evidence implicates TGFβ – 
along with platelet-derived growth factor, endothelin-1 
(ET-1), and other cytokines – in the pathogenesis of SSc. 
Accordingly, targeting the intracellular signaling path-
ways activated by TGFβ and other proﬁ  brotic mediators 
is a rational treatment strategy for controlling ﬁ  brosis 
and is an active area of current research.
Mediators of TGFβ responses
Canonical Smad signaling
Th   e canonical TGFβ signal transduction pathway involves 
sequential phosphorylation of the activin-like kinase-5 
type I TGFβ receptor and a group of intracellular 
signaling proteins called Smads [8]. When bound by 
active TGFβ, the cell surface TGFβ receptors transmit 
signals through phosphorylation of cytoplasmic Smad 
proteins, which translocate into the cell nucleus and 
trigger transcription of genes such as type I collagen, 
ﬁ  bro  nectin, α-smooth muscle actin and connective tissue 
growth factor (CTGF), each of which plays important 
roles in ﬁ  brogenesis [9]. Smad3 null mice are protected 
against bleomycin-induced ﬁ  brosis of the skin and lungs 
[10,11]. In addition, pharmacologic blockade of activin-
like kinase-5 activity with small molecule inhibitors such 
as SB431542 and SD208 results in complete abrogation of 
proﬁ   brotic responses induced by TGF  β, and 
normalization of the autonomously activated phenotype 
of SSc ﬁ  broblasts in vitro [12,13]. Selective blockade of 
Smad phosphorylation or of non-Smad signaling down-
stream of TGFβ using small molecules are promis  ing 
novel approaches to the treatment of ﬁ  brosis that are 
under investigation.
Figure 1. Characteristic radiographic fi  ndings on high-resolution 
computed tomography. High-resolution computed tomography of 
the chest reveals (a) subpleural ground glass opacities (white arrow) 
and traction bronchiectasis suggestive of nonspecifi  c interstitial 
pneumonia, and (b) honeycombing (black arrows) with ground glass 
opacities suggestive of usual interstitial pneumonia.
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In normal ﬁ   broblasts TGFβ induces activation of c-
Abelson tyrosine kinase (c-Abl), a member of the Src 
family of nonreceptor protein tyrosine kinases [14]. 
Trans  forming mutations of c-Abl are found in 95% of 
patients with chronic myelogenous leukemia, and result 
in constitutive kinase activity that is directly responsible 
for myeloid cell hyperproliferation [15]. Recent studies of 
c-Abl function in nonmyeloid cells reveal that c-Abl is 
directly activated by TGFβ, and integrates serine–
threonine kinase signaling with nonreceptor tyrosine 
kinase pathways [16].
Imatinib mesylate is a potent small molecule inhibitor 
of c-Abl, as well as of platelet-derived growth factor 
receptor activity. Inhibition of c-Abl kinase activity using 
imatinib was recently demonstrated to abrogate the 
stimulation of collagen gene expression in vitro, and to 
prevent the development of skin and lung ﬁ  brosis in vivo 
in animal models [14,17]. Preclinical studies show that, in 
explanted normal skin and lung ﬁ  broblasts,  imatinib 
eﬀ  ectively blocked TGFβ-induced stimulation of collagen 
synthesis and myoﬁ   broblast transformation, which are 
key events in the ﬁ   brotic response [18]. Furthermore, 
imatinib partially reversed the abnormal phenotype of 
SSc ﬁ  broblasts [17]. Since one of the downstream targets 
of c-Abl is the proﬁ  brotic transcription factor Egr-1 (see 
below), blockade of c-Abl activity might prevent ﬁ  brosis 
by inhibiting Egr-1 activation [19].
Anecdotal reports indicate therapeutic eﬃ   cacy  of 
imatinib in SSc, graft versus host disease, nephrogenic 
ﬁ   brosis, and other ﬁ   brosing conditions. Ongoing 
clinical trials are evaluating the eﬃ   cacy and safety of 
imatinib in SSc-associated ILD. Of note, however, a 
recently completed randomized controlled trial showed 
no beneﬁ   t of imatinib compared with placebo in 
patients with IPF [20].
Figure 2. Mechanisms perpetuating pulmonary fi  brosis. Pathogenesis of pulmonary fi  brosis is initiated by microvascular injury, which leads to 
endothelial cell damage and alveolar epithelial injury. This leads to activation of the coagulation cascade, release of various cytokines and growth 
factors, and ultimately activation of fi  broblasts, a key event in the development of fi  brosis. CTGF, connective tissue growth factor; IGF-1, insulin-like 
growth factor-1; LPA, lysophosphatidic acid; TGF-β, transforming growth factor beta.
Castelino and Varga Arthritis Research & Therapy 2010, 12:213 
http://arthritis-research.com/content/12/4/213
Page 4 of 11Egr-1
Egr-1 is a zinc ﬁ  nger DNA binding transcription factor 
that is rapidly and transiently induced at sites of injury. 
Egr-1 is implicated in cell proliferation, diﬀ  erentiation 
and survival, and plays a central role in orchestrating 
acute tissue responses to injury [21]. Egr-1 null mice were 
protected from pulmonary and skin ﬁ  brosis induced by 
TGFβ or by bleomycin, and Egr-1 was shown to be 
suﬃ     cient and necessary for the stimulation of type I 
collagen production in vitro [22]. Genome-wide expres-
sion proﬁ  ling using microarrays has demonstrated that 
abnormal Egr-1 expression in the lung was strongly 
associated with rapid progression of lung ﬁ  brosis  in 
patients with IPF [23]. In addition, both Egr-1 mRNA and 
protein were elevated in explanted SSc skin ﬁ  broblasts in 
vitro [24]. Egr-1 was also shown to be a key mediator of 
lung ﬁ  broblast activation induced by insulin-like growth 
factor (IGF) binding protein 5 [25].
Th  ese observations identify Egr-1 as a critical intra-
cellular mediator of lung ﬁ  brosis in humans and in mouse 
models. Ongoing studies are investigating blocking Egr-1 
expression or activity with drugs such as imatinib as 
potential strategies to control pathologic ﬁ  brosis.
Peroxisome proliferator-activated receptor gamma
Peroxisome proliferator-activated receptor gamma (PPARγ) 
is a nuclear steroid hormone receptor and a ligand-activated 
transcription factor. Originally described in adipocytes, it is 
now recognized that PPARγ is widely expressed in tissues 
and plays key regulatory roles not only in adipogenesis and 
insulin sensitivity, but also in inﬂ  ammation and immunity.
An emerging novel function for PPARγ is as an 
endogenous anti-ﬁ   brotic defense mechanism. Ligand 
activation of cellular PPARγ potently inhibited the activa-
tion of TGFβ-inducible responses in normal skin and 
lung ﬁ  broblasts [26]. It is notable that the expression of 
PPARγ is markedly reduced in lung biopsies from 
patients with SSc-associated ILD [27]. Ligands for induc-
ing the activity of PPARγ include endogenous natural 
agonists such as fatty acids or prostaglandins (PGJ2), and 
synthetic pharmacologic agents such as rosiglitazone and 
pioglitazone [28]. Th  ese drugs are in wide use for the 
treatment of type 2 diabetes. Rosiglitazone was recently 
shown to attenuate bleomycin-induced dermal ﬁ  brosis 
and inﬂ  ammation  in vivo. Furthermore, rosiglitazone 
prevents alveolar epithelial mesenchymal transition and 
also TGFβ-induced stimu  lation of collagen gene trans-
cription, myoﬁ  broblast  transdiﬀ   erentiation, and cell 
migration in normal ﬁ  broblasts [29].
In light of its potent anti-inﬂ   ammatory and anti-
ﬁ  brotic activities and relative safety in clinical practice, 
studies of existing PPARγ agonists – and novel selective 
agonists under development – are now warranted for 
treatment of ILD.
Endothelin-1
Endothelial injury in small and medium-sized arteries is a 
deﬁ   ning feature of SSc that leads to activation of the 
coagulation cascade followed by myoﬁ  broblast diﬀ  eren-
tiation, activation of endothelial cells, and capillary loss. 
ET-1 is a potent vasoconstrictor released by endothelial 
cells, epithelial cells and mesenchymal cells. In lung 
injury, ET-1 binds to ET-1A and ET-1B receptors, recruits 
ﬁ  broblasts and stimulates matrix production [30]. Trans-
genic mice overexpressing ET-1 develop lung ﬁ  brosis [31] 
and ET-1 levels are elevated in mouse models of 
bleomycin-induced ﬁ   brosis [32]. ET-1 also has been 
found to stimulate TGFβ secretion in lung ﬁ  broblasts 
[33]. Studies with bosentan, a dual-receptor ET-1 antago-
nist, are underway for the treatment of IPF and SSc-
associated ILD.
Growth factors and chemokines
Lysophosphatidic acid
Th  e bioactive phospholipid lysophosphatidic acid (LPA) 
and its receptor LPA1 have recently been implicated in 
the pathogenesis of IPF [34]. LPA is produced by acti-
vated platelets, as well as by ﬁ  broblasts.  Th  e LPA1 
receptor is expressed in ﬁ  broblasts, endothelial cells, and 
epithelial cells, and enables LPA to induce diverse bio-
logic eﬀ  ects involved in tissue responses to injury.
Both LPA and its receptor are required for the develop-
ment of lung ﬁ  brosis in a mouse model of IPF induced by 
bleomycin [34]. Th   ese studies revealed that the ﬁ  broblast 
chemoattractant activity present in the lungs of IPF 
patients is largely attributable to LPA, suggest  ing that 
LPA mediates ﬁ   broblast recruitment during the 
development of lung ﬁ  brosis. Preliminary results indicate 
that mice lacking the LPA1 receptor are protected from 
bleomycin-induced dermal ﬁ  brosis com  pared with wild-
type mice (FV Castelino, AM Tager, un  pub  lished data). 
Th  e LPA-LPA1 pathway therefore appears to be a 
promising novel therapeutic target for SSc-associated 
pulmonary ﬁ  brosis.
Insulin-like growth factor
IGFs and their binding proteins have been implicated in 
the pathogenesis of pulmonary ﬁ   brosis and SSc. 
Increased levels of IGF-1 are detected in the serum as 
well as in the bronchoalveolar lavage of patients with 
SSc-associated ILD [35]. In addition, blockade of the IGF 
pathway leads to resolution of pulmonary ﬁ  brosis in a 
mouse model of pulmonary ﬁ  brosis [36]. Th  ese obser-
vations raise the possibility that targeting the IGF path-
way may be a potential treatment of CTD-ILD.
Connective tissue growth factor
CTGF, also known as CCN2, is a small cysteine-rich 
matri  cellular protein with an important role in 
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Although the speciﬁ  c receptors for CTGF or the precise 
mechanism of action are poorly understood, CTGF acts 
as a downstream mediator of TGFβ, and may play a role 
in the stimulation of extracellular matrix production and 
myoﬁ  broblast diﬀ  erentiation.
Levels of CTGF are elevated in the skin and lungs from 
patients with SSc, as serum levels of CTGF reﬂ  ect disease 
severity. Lung ﬁ   broblasts explanted from bleomycin-
injected mice have a high expression of CTGF [38]. 
CTGF is therefore an attractive target for the treatment 
of pulmonary ﬁ   brosis, and clinical trials using a 
monoclonal anti-CTGF antibody are under preparation.
Treatment considerations
To date there is no cure or eﬀ  ective disease-modifying 
therapy for any form of CTD-ILD. d-Penicillamine and 
colchicine are largely ineﬀ   ective [39,40]. Because 
evidence of inﬂ  ammation is commonly present in early-
stage disease, current therapies for SSc-associated ILD 
target the inﬂ   ammatory response. Th  e immuno  sup-
pressive agents most widely used for this purpose are 
corticosteroids, cyclophosphamide, azathioprine, and 
myco  phenolate mofetil. While corticosteroids are 
generally ineﬀ  ective, other agents have demonstrated a 
modest beneﬁ  cial eﬀ  ect.
In contrast to various rheumatic diseases where 
immuno  suppressives have been helpful, immunosup-
pres  sive therapies in CTD-ILD have not led to complete 
responses. Th  ere is only limited experience with newer 
biologicals such as anti-TNF therapies or rituximab.
Cyclophosphamide
Multiple studies and uncontrolled trials of CTD-ILD 
have reported beneﬁ  cial  eﬀ   ects of cyclophosphamide 
administered orally or intravenously [40-42]. Th  ese  studies 
showed improvement in respiratory symptoms, lung 
function, radiologic ﬁ  ndings, and bronchoalveolar lavage 
inﬂ  ammation, as well as survival.
Th   e Scleroderma Lung Study was the ﬁ  rst multicenter, 
randomized placebo-controlled clinical trial to evaluate 
the eﬀ   ectiveness of oral cyclophosphamide in SSc-
associated ILD [43]. In the study, 158 patients with early-
stage SSc and symptomatic ILD with radiologic or 
bronchoalveolar lavage evidence of alveolar inﬂ  ammation 
were randomized to cyclophosphamide or placebo. A 
12-month course of active therapy was associated with a 
modest but statistically signiﬁ   cant improvement in 
forced vital capacity (FVC), but no change in diﬀ  using 
capacity for carbon monoxide. Furthermore, respiratory 
symptoms and chest radiologic abnormalities showed 
improvement [43,44]. Th  e response in pulmonary func-
tion was most pronounced in those patients with the 
most advanced lung disease at baseline. At 24-month 
follow-up, the beneﬁ  cial eﬀ  ect of cyclophosphamide on 
pulmonary function largely disappeared. In contrast, 
beneﬁ   cial responses in skin score and quality of life 
measures persisted at 2 years.
A randomized, double-blind, placebo-controlled study 
from the UK compared the eﬃ   cacy  of  intravenous 
cyclophosphamide combined with corticosteroids and 
followed by azathioprine with that of placebo. Th  is  study 
of 45 SSc patients with early ILD demonstrated a 
favorable out  come in the treatment group, but, due to the 
small size of the study, the results did not achieve 
statistical signiﬁ    cance [45].
Mycophenolate mofetil
Mycophenolate mofetil is an immunosuppressive drug 
with less toxicity compared with cyclophosphamide. One 
study evaluated 17 patients with SSc-associated ILD 
treated with mycophenolate mofetil for up to 24 months 
[46]. At 12 months the FVC and diﬀ  using capacity for 
carbon monoxide had improved by 2.6% and 1.4%, res-
pec  tively, while at 24 months the increase in FVC was 
2.4% [46]. Gerbino and colleagues evaluated myco  pheno-
late mofetil in 13 patients with early SSc-associated ILD 
[47]. Th   e FVC improved by a mean of 4% predicted at a 
median of 21 months. Th  e ongoing Scleroderma Lung 
Study II will compare the eﬃ   cacy and safety of myco-
phenolate mofetil with cyclophosphamide in patients 
with SSc-associated ILD.
Azathioprine
Azathioprine is an alternative agent for SSc-associated 
ILD. Patients with a milder form of ILD or those unable to 
tolerate cyclophosphamide may be potential candidates.
A retrospective analysis described 11 patients with 
SSc-associated ILD who received azathioprine and 
prednisone [48]. In this study, 8/11 patients showed an 
improvement in FVC and dyspnea scores at 12 months.
Data also suggest a role for azathioprine as maintenance 
therapy following intravenous cyclophosphamide. A 
retrospective series of 27 patients with SSc-associated 
ILD showed stabilization or improvement of lung func-
tion with a combination regimen of monthly intra  venous 
cyclophosphamide given for 6 months followed by 
18 months of azathioprine [49].
Endothelin-1 receptor antagonists
Bosentan is a dual ET-1 receptor antagonist approved 
for the treatment of pulmonary arterial hypertension. 
ET-1 is overexpressed in SSc skin and lungs, and can act 
as a proﬁ  brotic cytokine that promotes myoﬁ  broblast 
proliferation.
Th  e Bosentan in Interstitial Lung Disease (BUILD 1) 
study examined the potential anti-ﬁ  brotic  eﬃ   cacy  of 
bosentan in IPF. One hundred and ﬁ  fty-eight patients 
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placebo [50]. With the 6-minute walk test as primary out-
come at 12 months, bosentan was no better than placebo. 
Moreover, a recent placebo-controlled trial of bosentan 
for the treatment of SSc-associated ILD patients 
(BUILD 2) was terminated due to lack of eﬃ   cacy [51], 
and BUILD  3 – evaluating the safety and eﬃ   cacy  of 
bosentan in IPF patients – did not meet the primary 
endpoint of a reduction in morbidity and mortality 
(unpublished data).
Tyrosine kinase inhibitors
Th  e therapeutic use of small molecule kinase inhibitors 
for nonmalignant diseases has generated a great deal of 
interest, but their use is limited by toxicity. In contrast to 
inhibitors of ubiquitous protein kinases such as p38, 
imatinib mesylate (Gleevec®; Imatinib mesylate, Novartis, 
Basel, Switzerland) selectively blocks the activity of the c-
Abl tyrosine kinase and, to a lesser degree, the platelet-
derived growth factor receptor and c-kit, and appears to 
have a relatively favorable long-term safety proﬁ  le in a 
large number of chronic myelogenous leukemia patients.
Individual case reports provide support for the use of 
imatinib in SSc. Van Daele and colleagues described a 
patient with SSc who had progressive pulmonary ﬁ  brosis 
despite treatment with intravenous cyclophosphamide 
[52]. After 5 months of imatinib, improvement in skin 
score (from 18 to 12) and pulmonary function was noted. 
Another report described a woman with longstanding 
and progressive SSc unresponsive to intravenous cyclo-
phosphamide and mycophenolate mofetil [53]. Th  is 
patient showed improved skin and stabilization in lung 
function after 6 months of imatinib therapy [53]. In 
contrast, a recent large, multicenter, randomized con-
trolled trial of imatinib versus placebo in the treatment of 
IPF showed no signiﬁ  cant beneﬁ  t [20].
Pirfenidone
Pirfenidone is a pyridone with both anti-inﬂ  ammatory 
and anti-ﬁ  brotic eﬀ  ects. Pirfenidone was shown to inhibit 
collagen synthesis and TGFβ production in vivo in animal 
models of IPF [54]. In clinical studies, pirfenidone slowed 
a decline in lung function and exercise capacity [55]. A 
randomized, double-blind, placebo-controlled phase III 
trial in IPF (CAPACITY 1 trial) demonstrated a decrease 
in the rate of decline of vital capacity and an increase in 
progression-free survival time over 52 weeks; however, 
the primary endpoint of change in the percentage 
predicted FVC at week 72 was not met [56]. Th  e 
CAPACITY 2 trial, using a lower dose of pirfenidone, 
reached its primary endpoint [57]. Pirfenidone was 
administered to two patients with SSc-associated ILD 
[58]. Th  ese patients showed no signiﬁ  cant radiological 
progression or functional deterioration. One should note, 
however, that the Food and Drug Administration recently 
rejected the use of pirfenidone for the treatment of IPF, 
citing the need for an additional clinical trial to prove 
eﬃ   cacy given that the drug worked in one of the two 
trials and questioning whether the beneﬁ  t provided by 
the drug was meaningful (InterMune press release).
Lung transplantation
Lung transplantation remains an option for SSc patients 
with ILD who fail to respond to pharmacologic therapy. 
A recent study comparing lung transplantation in 29 
patients presenting SSc-associated ILD with 70 patients 
presenting IPF showed comparable cumulative survival 
(64%) at 2 years [59]. In another retrospective analysis, 23 
of 47 SSc patients were alive at 24 months post lung 
transplantation [60].
Prognosis of systemic sclerosis-associated 
interstitial lung disease
ILD is a leading cause of morbidity and mortality in SSc. 
Th  e prognosis of SSc-associated ILD depends on the 
underlying pathology. Th  e NSIP pattern has a more 
favorable outcome compared with the UIP pattern 
characteristically associated with IPF [61]. A recent 
retrospective review of 80 patients with SSc-associated 
ILD showed that 76% had an NSIP pattern and 11% had a 
UIP pattern [61,62]. In this study, the 5-year survival 
rates were similar for patients with the NSIP pattern and 
the UIP pattern (82% and 91%, respectively). It is diﬃ   cult 
to predict whether IPF patients with a UIP pattern would 
have similar survival as SSc patients with a UIP pattern.
Other connective tissue disease-associated 
interstitial lung diseases
Rheumatoid arthritis
Lung disease is a leading cause of death in RA, second 
only to infection. Evidence of ILD is seen in 20 to 30% of 
patients, but the reported prevalence varies depending 
on the criteria used for diagnosis [63]. Most RA patients 
show pulmonary parenchymal abnormalities on HRCT, 
including bronchial wall thickening, bronchial dilation, 
micronodules, and opacities, along with pleural eﬀ  usions.
Th   e main ﬁ  nding in patients with ILD is bibasilar sym-
metrical reticular inﬁ  ltrates followed by honeycombing. 
Th   e histologic NSIP pattern was previously thought to be 
most frequent in RA, but recent studies of surgical lung 
biopsies reveal that the UIP pattern may be more 
common [64]. Th  e 5-year survival in RA patients with 
UIP is less than 50%. In one study, RA patients had a 
greater number of CD4-positive T cells in the broncho-
alveolar lavage ﬂ  uid than IPF patients [65].
Little is known regarding the optimal therapy of RA-
associated lung disease, and randomized trials are 
lacking. Corticosteroids and immunosuppressive agents 
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limited beneﬁ  t in RA UIP [66]. In IPF, N-acetylcysteine 
added to a regimen of prednisone and azathioprine 
slowed deterioration of the FVC and diﬀ  using capacity 
for carbon monoxide at 12 months [67]. Mycophenolate 
mofetil is another therapeutic consideration in patients 
with RA-associated ILD. One report of two RA patients 
with ILD showed beneﬁ  t of mycophenolate mofetil on 
pulmonary function and radiologic abnormalities [68]. 
While the course of RA-associated ILD varies from a 
slow progression to a fulminant course, the prognosis is 
generally better than that of IPF.
Polymyositis/dermatomyositis
Th  e presence of ILD markedly inﬂ   uences the disease 
course in inﬂ  ammatory myositis. Th   e reported incidence 
of ILD varies from 20 to 54% depending on the criteria 
used for diagnosis [69,70]. Th   e strongest predictive factor 
is the presence of autoantibodies to aminoacyl tRNA 
synthetase, most commonly anti-Jo-1 [71]. Another 
serum marker of increased risk for ILD is antibody to 
KL-6, a glycoprotein expressed on type II alveolar and 
bronchiolar epithelial cells [72]. Amyopathic dermato-
myositis is also associated with ILD and can have a poor 
prognosis [73]. In addition, anti-clinically amyo  pathic 
dermatomyositis antibodies associated with this subset 
suggest rapidly progressive ILD [74].
Th   e histopathology of ILD in PM/DM includes crypto-
genic organizing pneumonia, diﬀ   use alveolar damage, 
and NSIP and UIP patterns [75]. One study suggested 
that patients with a cryptogenic organizing pneumonia 
pattern respond to corticosteroids, while those with 
diﬀ  use alveolar damage and UIP patterns do not [75].
Th   ere are no controlled trials evaluating the treatment 
of PM/DM-associated ILD. Th  e most common initial 
therapy uses corticosteroids, generally at a dose of 
1 mg/kg/day prednisone for 6 to 8 weeks, followed by a 
gradual taper. Steroid-sparing immunosuppressive agents 
such as cyclophosphamide, azathioprine, and metho-
trexate are frequently used. For some patients whose 
disease is rapidly progressive, either oral steroids or pulse 
methylprednisolone combined with monthly intravenous 
cyclophosphamide has been reported to show a favorable 
response [76].
One report described the use of tacrolimus in two 
myositis patients with progressive ILD who had failed 
cyclophosphamide and high-dose corticosteroid treat-
ment [77]. Th  ese patients showed signiﬁ  cant improve-
ment in symptoms and radiologic abnormalities. In 
another report, 12 out of 15 PM/DM patients treated 
with tacrolimus for up to 36 months showed signiﬁ  cant 
improvement in all pulmonary parameters [78].
Rituximab has also been used in the treatment of 
myositis and anti-synthetase syndromes. In a retro  spec  tive 
case series, rituximab appeared to stabilize ILD in seven 
out of 11 patients during the ﬁ   rst 6 months after 
treatment [79]. In addition, in a study of 49 patients with 
DM/PM, 75% showed a good response in myositis 
features after treatment with rituximab [80].
Sjögren’s syndrome
ILD develops in approximately 25% of patients with 
Sjögren’s syndrome [81]. In these patients, ILD charac-
teristically presents with cough, dyspnea, and bilateral 
pulmonary inﬁ  ltrates on chest radiographs.
Th  e lymphocytic interstitial pneumonia pattern was 
previously suggested to be the most characteristic histo-
pathology in Sjögren’s syndrome, but recent studies show 
that the NSIP pattern is more prevalent [81,82]. Lympho-
cytic interstitial pneumonia represents a benign poly-
clonal proliferation of mature B cells or T cells that can 
involve the lung either diﬀ  usely or focally. Lymphocytic 
interstitial pneumonia is also considered relatively 
respon  sive to steroid therapy [81].
Th   e optimal treatment for patients with Sjögren’s 
syndrome-associated ILD is not known. Anecdotal 
reports and small case series suggest the disease is steroid 
responsive. While the majority of patients experienced 
rapid subjective improvement, pulmonary function tests 
and radiological abnormalities showed a slower response 
over several months [82]. Some patients require addi-
tional immunosuppressive agents such as azathio  prine or 
cyclophosphamide.
Systemic lupus erythematosus
Pulmonary involvement is frequent in SLE, and can aﬀ  ect 
the pleura, pulmonary vasculature, and parenchyma. Th  e 
prevalence and severity of ILD appears to be lower in SLE 
than in the other CTDs. Acute lupus pneumonitis is an 
uncommon manifestation of SLE [83]. Th  e disease 
typically presents with acute dyspnea, cough, fever, and 
pleuritic pain, and occasionally with pulmonary hemor-
rhage. Diﬀ  use ILD or chronic pneumonitis in SLE occurs 
in 3 to 8% of patients [83].
Th   e treatment for SLE-associated ILD is to some extent 
dictated by the predominant lung pathology. In patients 
with acute lupus pneumonitis, the mainstay of treatment 
is oral prednisone (1 mg/kg/day). If there is no prompt 
improvement, then intravenous methylprednisolone with 
an immunosuppressive agent such as cyclophosphamide 
is commonly used. One report described a patient with 
acute lupus pneumonitis who responded to weekly 
rituximab with a rapid improvement in subjective symp-
toms and pulmonary function test abnormalities [84].
Undiff  erentiated connective tissue disease
Patients with undiﬀ   erentiated CTD often have some 
features of a rheumatic disease but do not have suﬃ   cient 
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patients may have a concomitant ILD that either precedes 
or occurs concomitantly with their rheumatic symptoms. 
In a case–control study evaluating 28 patients with idio-
pathic interstitial pneumonia, 88% of patients classiﬁ  ed 
with an initial histologic pattern of idiopathic NSIP had 
features of an undiﬀ   erentiated CTD [86]. In addition, 
patients with undiﬀ   erentiated CTD had a substantial 
improvement in FVC during a follow-up period of 8 
months compared with IPF patients [87]. Treatment of 
undiﬀ  erentiated CTD-ILD is similar to other CTD-ILDs 
with an NSIP pattern.
Mixed connective tissue disease
Pulmonary involvement is a common complication of 
mixed CTD. Up to two-thirds of patients have a reduced 
diﬀ   using capacity for carbon monoxide, and approxi-
mately one-half have evidence of restrictive abnormalities 
on pulmonary function tests [88]. Th  e predominant 
radiologic abnormality in the chest is ground glass 
opacities associated with septal thickening with a lower 
lobe predominance [89]. Th  ese ﬁ   ndings are similar to 
those seen in SSc-associated ILD. Treatment of ILD in 
mixed CTD is similar to that of other CTD-ILDs. In one 
study, 47% of patients with mixed CTD-ILD responded 
to corticosteroids at a dose of 2 mg/kg/day [89].
Conclusion
ILD is now increasingly recognized as a frequent and 
serious complication of rheumatic diseases and CTDs. 
Eﬀ   ective disease-modifying therapies are still lacking, 
and many of the currently used treatments are largely 
ineﬀ  ective. Stem cell therapies and novel agents including 
rituximab, angiotensin II inhibitors, tyrosine kinase 
inhibitors, PPARγ agonists, intravenous immunoglobulin, 
and biologicals targeting chemokines, cytokines, and 
growth factors are in preclinical or clinical studies. Th  ere 
is progress towards better understanding the patho-
genesis of CTD-ILD, and the role of growth factors, 
chemokines, and lipid mediators. Serum biomarkers as 
either indicators of pulmonary ﬁ  brosis or indicators of 
disease progression are under active investigation. 
Despite these impressive recent advances, the manage-
ment of patients with CTD-ILD remains unsatisfactory. 
Further study into the cell types, mediators, and pathways 
involved in lung ﬁ  brosis is urgently needed. Th  ese  further 
studies may lead to a better understanding of lung 
ﬁ   brosis, and to the development of safer and more 
eﬀ  ective rational therapies.
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